Population

The study included PLWTB in Greater Accra, Ghana, who were l5 years or older, had been diagnosed with the TB disease and were being managed with antituberculosis medication through DOTS. The PLWTB were included in the study irrespective of their site of TB infection (pulmonary or extrapulmonary TB), comorbidity status (TB with HIV, diabetes mellitus or pleuritis with pleural effusion) or duration of TB treatment. The study excluded PLWTB who had been diagnosed with drug-resistant TB. The exclusion was on account of the difference in TB treatment regimens for persons living with drug-sensitive and drug-resistant TB. Respondents’ sample size was determined prior to the study using G*Power software (version 3.1.9.7). We assumed an effect size of 0.5, a power of 0.8 and an alpha value of 0.05 (two-tailed) which yielded a minimum of 128 respondents [29]. Nonetheless, 250 PLWTB were sampled to account for non-response and ensure adequate respondent sampling.